Gopinathan Suma 4

What Happened

• Gopinathan Suma, Senior Vice President, Discovery at Lexicon Pharmaceuticals (LXRX), received two awards of restricted stock units (RSUs) on February 12, 2026: 238,450 RSUs and 357,680 RSUs, for a total of 596,130 RSUs. Each RSU was reported at $0.00 at grant and is a derivative security representing a contingent right to one share of common stock upon vesting.

Key Details

• Transaction date: 2026-02-12. Report filed: 2026-02-17 (appears to be filed late; Form 4 is generally due within 2 business days of the transaction).
• Grant amounts and prices: 238,450 RSUs @ $0.00 and 357,680 RSUs @ $0.00 (total 596,130 RSUs).
• Shares owned after transaction: Not specified in the filing.
• Footnotes from the filing:
  • F1: Each RSU represents a contingent right to receive one share of common stock.
  • F2: RSUs vest 1/3 on February 28 of each of the three years following the year of grant.
  • F3 (not directly applicable to these RSU grants): describes option vesting schedule (25% at 1 year, then monthly thereafter).
• Transaction type: Award/Grant (derivative securities). No sale or purchase of underlying shares occurred at grant.

Context

• RSUs are not immediate open-market purchases—these awards convert into shares only as they vest per the schedule above. Such grants are common for employee incentives and do not by themselves indicate an immediate change in market exposure by the insider.
• Because the Form 4 was filed several days after the transaction date, retail investors may want to note the timeliness issue but should focus on the award terms and vesting schedule when assessing potential future insider holdings.